Skip to content
RNAWiki
Checking…
All public datasets

Public dataset

Recorded source agreement and disagreement

Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.

What this does not mean: agree can mean only that sources print the same normalized reading; it is not clinical-context equivalence, independent replication, or proof. differ requires matching structured context and disjoint comparable values. not_comparable and insufficient_context are not disagreement.
Public rows
1,681
Generated
Schema version
source-consensus/2

Coverage

What this run contains

Compared medicine fields
1,681
Agree
1,282
Differ
0
Not comparable
12
Insufficient context
387
Fields represented
5
bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution

Method

How the rows were made

  1. Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
  2. One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
  3. Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
  4. not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
  5. The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
  6. Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
  7. documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.

Limits

Read these before using a row

  • Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
  • The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
  • Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
  • Only the recorded fields and source documents in this snapshot are compared.
  • A source count is the number of retained source records in the row, not a count of independent experiments.

Provenance

Source examples

abacavir · bioavailability · agree

15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
The geometric mean absolute bioavailability of the tablet was 83%.

alemtuzumab · volumeOfDistribution · not_comparable

2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)
Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).

abiraterone · halfLife · insufficient_context

31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.

Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
fieldstringRecorded pharmacokinetic field being compared.
comparisonStatestringagree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero.
comparisonReasonsstring[]Deterministic codes explaining the state.
documentsExaminednumberRecorded source documents considered for the field.
sourceCountnumberRecorded source readings represented.
agreementRatenumberShare represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability.
readingsconsensus-reading[]Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact comparability state.

Exact recorded field key.

Clear

Showing 461–470 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 461

    Medicine slug
    dofetilide
    Compared field
    proteinBinding
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    13
    Source count
    13
    Agreement rate
    0.923077
    Recorded readings

    1. 60 to 70%

      Numeric value
      60
      Unit
      %
      Source records
      12

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 12 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4c1a5a6d-bd69-473c-8caa-d0d242b7708d (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Plasma protein binding of dofetilide is 60 to 70%, is independent of plasma concentration, and is unaffected by renal impairment.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4552d82a-dd28-410c-9642-1af060832b47 (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Plasma protein binding of dofetilide is 60 to 70%, is independent of plasma concentration, and is unaffected by renal impairment.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:41ccbb23-ae03-44bd-b438-0b0a8388d56b (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Plasma protein binding of dofetilide is 60 to 70%, is independent of plasma concentration, and is unaffected by renal impairment.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a5d943c6-1960-4318-9e6f-6bf69ac49953 (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Plasma protein binding of dofetilide is 60–70%, is independent of plasma concentration, and is unaffected by renal impairment.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:26de5f8c-8cec-46f6-a468-69451758a278 (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Plasma protein binding of dofetilide is 60-70%, is independent of plasma concentration, and is unaffected by renal impairment.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b8323987-90fe-4e6c-a71c-76e3c501713c (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Plasma protein binding of dofetilide is 60–70%, is independent of plasma concentration, and is unaffected by renal impairment.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:85f2b35c-31d5-4161-b342-c781d23945a5 (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Plasma protein binding of dofetilide is 60 to 70%, is independent of plasma concentration, and is unaffected by renal impairment.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:02438044-d6a3-49e9-a1ac-3aad21ef2c8c (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Plasma protein binding of dofetilide is 60–70%, is independent of plasma concentration, and is unaffected by renal impairment.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cff8d66a-ed43-46dd-97de-3dd21a7f2572 (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Plasma protein binding of dofetilide is 60–70%, is independent of plasma concentration, and is unaffected by renal impairment.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:28fe0cac-62fd-997d-8065-561aaf1541c4 (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Plasma protein binding of dofetilide is 60-70%, is independent of plasma concentration, and is unaffected by renal impairment.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0cb2ef7d-e35b-483b-9985-cfef99d7b96f (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Plasma protein binding of dofetilide is 60–70%, is independent of plasma concentration, and is unaffected by renal impairment.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e6caaf44-4a3e-46ef-85fa-f97f682fbdd6 (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Plasma protein binding of dofetilide is 60 to 70%, is independent of plasma concentration, and is unaffected by renal impairment.

    2. 60%

      Numeric value
      60
      Unit
      %
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0e60aa4b-72c2-4ef4-ab01-c9cf94240ff1 (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Plasma protein binding of dofetilide is 60% to 70%, is independent of plasma concentration, and is unaffected by renal impairment.

  2. Projected row 462

    Medicine slug
    dofetilide
    Compared field
    volumeOfDistribution
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    13
    Source count
    13
    Agreement rate
    1
    Recorded readings

    1. 3 L/kg

      Numeric value
      3
      Unit
      L/kg
      Source records
      13

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 13 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4c1a5a6d-bd69-473c-8caa-d0d242b7708d (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Volume of distribution is 3 L/kg.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4552d82a-dd28-410c-9642-1af060832b47 (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Volume of distribution is 3 L/kg.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0e60aa4b-72c2-4ef4-ab01-c9cf94240ff1 (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Volume of distribution is 3 L/kg.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:41ccbb23-ae03-44bd-b438-0b0a8388d56b (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Volume of distribution is 3 L/kg.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a5d943c6-1960-4318-9e6f-6bf69ac49953 (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Volume of distribution is 3 L/kg.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:26de5f8c-8cec-46f6-a468-69451758a278 (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Volume of distribution is 3 L/kg.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b8323987-90fe-4e6c-a71c-76e3c501713c (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Volume of distribution is 3 L/kg.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:85f2b35c-31d5-4161-b342-c781d23945a5 (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Volume of distribution is 3 L/kg.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:02438044-d6a3-49e9-a1ac-3aad21ef2c8c (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Volume of distribution is 3 L/kg.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cff8d66a-ed43-46dd-97de-3dd21a7f2572 (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Volume of distribution is 3 L/kg.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:28fe0cac-62fd-997d-8065-561aaf1541c4 (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Volume of distribution is 3 L/kg.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0cb2ef7d-e35b-483b-9985-cfef99d7b96f (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Volume of distribution is 3 L/kg.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e6caaf44-4a3e-46ef-85fa-f97f682fbdd6 (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Volume of distribution is 3 L/kg.

  3. Projected row 463

    Medicine slug
    dolutegravir
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    2
    Source count
    2
    Agreement rate
    1
    Recorded readings

    1. 14 hours

      Numeric value
      14
      Unit
      hours
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:63df5af3-b8ac-4e76-9830-2dbb340af922 (opens source in a new tab)

        Dolutegravir label

        Version not recorded · Effective date not recorded

        Elimination Dolutegravir has a terminal half-life of approximately 14 hours and an apparent clearance (CL/F) of 1.0 L/h based on population pharmacokinetic analyses.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:485bc9db-8665-9f5a-e063-6394a90a7921 (opens source in a new tab)

        Dolutegravir label

        Version not recorded · Effective date not recorded

        Elimination Dolutegravir has a terminal half-life of approximately 14 hours and an apparent clearance (CL/F) of 1.0 L/h based on population pharmacokinetic analyses.

  4. Projected row 464

    Medicine slug
    donepezil
    Compared field
    proteinBinding
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    52
    Source count
    52
    Agreement rate
    1
    Recorded readings

    1. 75%

      Numeric value
      75
      Unit
      %
      Source records
      52

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 52 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5d46ef3c-0dee-4389-a2d5-997ea8342817 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2-1000 ng/mL.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1c6e8d7f-5219-4b6c-a1ce-2baff28c3d55 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2 to 1000 ng/mL.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:12ae85f0-023c-49ca-8c4a-0a6a7585290e (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2 to 1000 ng/mL.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:48178cb4-4fee-47c0-88e9-a4f017f1f448 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2-1000 ng/mL.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9407258b-60ed-4884-a903-885aeedaddf8 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2 to 1000 ng/mL.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c030fd7c-da5c-457a-a825-1767bd87d04d (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2 to 1000 ng/mL.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0516d548-db9b-410a-aec9-79aedbc3f6e9 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2 to 1000 ng/mL.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c942a4c9-dbe5-4131-bb6c-aa2d31b387e7 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2 to 1000 ng/mL.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ecf91436-9de1-44bb-8366-8551479c86a9 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2 -1000 ng/mL.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c7e1f642-1bdc-4ed6-9b9e-c1af40b926cd (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2 to 1000 ng/mL.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:76bf638e-dbde-418e-8977-1caf009990bc (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2 to 1000 ng/mL.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8138f616-83f3-4c47-84ef-1bce2db339f7 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2 to 1000 ng/mL.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:32709bda-53d0-4d57-9f0b-3e1f28e39f25 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha1 -acid glycoprotein (about 21%) over the concentration range of 2-1000 ng/mL.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:37aa1285-774a-4714-a4af-4e3fa9fa7f55 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2-1,000 ng/mL.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7db089de-0344-4246-81b7-7c88a2a18402 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2 -1000 ng/mL.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:11ac01f4-d26e-47b2-9660-d514ab097fdb (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2 to 1000 ng/mL.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ee54a472-6783-41df-b8bb-9c3e4c996907 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2 -1000 ng/mL.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a085ed33-c262-44ab-e053-2a95a90a5557 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha1 -acid glycoprotein (about 21%) over the concentration range of 2-1000 ng/mL.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:12a755c5-1ad9-43d1-832a-eb2ff17bd693 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha1 -acid glycoprotein (about 21%) over the concentration range of 2-1000 ng/mL.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2d01fb96-c825-fad5-e063-6394a90ac6cc (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2 to 1000 ng/mL.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0c6b12e8-1933-40d8-bf43-97339b2b54fb (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha1 -acid glycoprotein (about 21%) over the concentration range of 2-1000 ng/mL.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:93dddf28-094b-dd8c-e053-2995a90a63e9 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha1 - acid glycoprotein (about 21%) over the concentration range of 2-1000 ng/mL.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:84d8ca68-26f3-4dd5-9dd4-6a7525a30db1 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2 to 1000 ng/mL.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c777ddc9-0b61-4d6f-95d6-818ba1861d62 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2 to 1000 ng/mL.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6e9aacf9-abb6-4dec-9a8d-4eabf934d512 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2 ng/mL to1,000 ng/mL.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1a8906ce-96dc-4bc8-81c1-5db67a187aac (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2-1000 ng/mL.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8090bff0-e0f0-4846-a2ab-cb28a0a2648d (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha1 -acid glycoprotein (about 21%) over the concentration range of 2-1000 ng/mL.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bc570682-413b-46fb-a069-c2986884bfce (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2 to 1000 ng/mL.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7620f41a-3eef-453b-a564-ea3c85374de2 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 -acid glycoprotein (about 21%) over the concentration range of 2-1000 ng/mL.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cb1b3ed1-6e68-08e2-e053-2995a90a68c4 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha1 - acid glycoprotein (about 21%) over the concentration range of 2-1000 ng/mL.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e2ab403a-ec2d-44e7-9da1-66d0a7443f1d (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2 to 1000 ng/mL.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:06dd25a5-1bf2-446d-ad75-ff9d55117660 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 -acid glycoprotein (about 21%) over the concentration range of 2-1000 ng/mL.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:98e451e1-e4d7-4439-a675-c5457ba20975 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2-1000 ng/mL.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c26d9bf3-e148-48bb-8f4f-e8c73804b311 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2-1000 ng/mL.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:297e86e8-d248-4cc9-9d9c-2ef9efb4414d (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2 -1000 ng/mL.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7ab9d0ef-e30c-46e9-9911-435a7b65c47b (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2 -1000 ng/mL.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:de96349a-5fee-4de9-921c-e453d44b3203 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2 to 1000 ng/mL.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:56abe961-ec94-4a77-b548-426f6255539e (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2 ng/mL to1,000 ng/mL.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3257494f-8f44-4978-b92d-bde87b2444b6 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2 to 1000 ng/mL.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ac857917-74db-4591-be9f-d1c822c68c81 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha1 -acid glycoprotein (about 21%) over the concentration range of 2-1000 ng/mL.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:385d2fb5-814c-44bd-ac7b-8857d18f144b (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2 -1000 ng/mL.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:41c095b6-acd9-4627-a813-bbca7ecafee5 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2-1000 ng/mL.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:042a59ea-131a-4806-b0f4-2f791d4414e2 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2-1000 ng/mL.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4747633b-ac32-455e-8d50-ce9c481480c0 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 -acid glycoprotein (about 21%) over the concentration range of 2-1000 ng/mL.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:79ad107b-bb20-4ed3-89f0-d7c862f3957c (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha1 - acid glycoprotein (about 21%) over the concentration range of 2 to 1,000 ng/mL.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:86b0c5a0-ff3c-4840-a4ac-82af922d58bf (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2 to 1000 ng/mL.
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:03e26183-3e07-45e8-a414-a8bad32483e2 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2 to 1000 ng/mL.
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:37fc6638-4a63-4582-a64c-3525f8ed7ef2 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2 to 1000 ng/mL.
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:11404dc3-1bde-4d4e-8386-006b67ee19dd (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha1 - acid glycoprotein (about 21%) over the concentration range of 2-1000 ng/mL.
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7c0d3bcb-157d-0414-64ee-055bc614d190 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 - acid glycoprotein (about 21%) over the concentration range of 2 to 1000 ng/mL.
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aa2c22b8-2dd4-4916-bc4f-9995eab74a6e (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha 1 -acid glycoprotein (about 21%) over the concentration range of 2-1000 ng/mL.
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:caebc31c-5a35-4434-b7e2-80f6405383ca (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Donepezil is approximately 96% bound to human plasma proteins, mainly to albumins (about 75%) and alpha1 -acid glycoprotein (about 21%) over the concentration range of 2-1000 ng/mL.

  5. Projected row 465

    Medicine slug
    donepezil
    Compared field
    tMax
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    52
    Source count
    41
    Agreement rate
    1
    Recorded readings

    1. 8 hours

      Numeric value
      8
      Unit
      hours
      Source records
      41

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 41 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1c6e8d7f-5219-4b6c-a1ce-2baff28c3d55 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for donepezil hydrochloride 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil hydrochloride 10 mg tablets.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:12ae85f0-023c-49ca-8c4a-0a6a7585290e (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer's disease, following oral dosing, peak plasma concentration is achieved for donepezil hydrochloride 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil hydrochloride 10 mg tablets.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9407258b-60ed-4884-a903-885aeedaddf8 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for donepezil hydrochloride 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil hydrochloride 10 mg tablets.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c030fd7c-da5c-457a-a825-1767bd87d04d (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for donepezil hydrochloride 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil hydrochloride 10 mg tablets.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0516d548-db9b-410a-aec9-79aedbc3f6e9 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for donepezil hydrochloride 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil hydrochloride 10 mg tablets.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ecf91436-9de1-44bb-8366-8551479c86a9 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for donepezil 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil 10 mg tablets.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c7e1f642-1bdc-4ed6-9b9e-c1af40b926cd (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for donepezil hydrochloride 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil hydrochloride 10 mg tablets.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8138f616-83f3-4c47-84ef-1bce2db339f7 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for donepezil hydrochloride 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil hydrochloride 10 mg tablets.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:32709bda-53d0-4d57-9f0b-3e1f28e39f25 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for donepezil hydrochloride 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil hydrochloride 10 mg tablets.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:37aa1285-774a-4714-a4af-4e3fa9fa7f55 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer's disease, following oral dosing, peak plasma concentration is achieved for Donepezil Hydrochloride 23 mg tablets in approximately 8 hours, compared with 3 hours for Donepezil Hydrochloride 10 mg tablets.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7db089de-0344-4246-81b7-7c88a2a18402 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for donepezil 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil 10 mg tablets.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:11ac01f4-d26e-47b2-9660-d514ab097fdb (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for donepezil hydrochloride 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil hydrochloride 10 mg tablets.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ee54a472-6783-41df-b8bb-9c3e4c996907 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for donepezil 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil 10 mg tablets.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a085ed33-c262-44ab-e053-2a95a90a5557 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for donepezil hydrochloride 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil hydrochloride 10 mg tablets.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:12a755c5-1ad9-43d1-832a-eb2ff17bd693 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for donepezil hydrochloride 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil hydrochloride 10 mg tablets.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2d01fb96-c825-fad5-e063-6394a90ac6cc (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for donepezil hydrochloride 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil hydrochloride 10 mg tablets.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0c6b12e8-1933-40d8-bf43-97339b2b54fb (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for donepezil hydrochloride 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil hydrochloride 10 mg tablets.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:84d8ca68-26f3-4dd5-9dd4-6a7525a30db1 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for donepezil hydrochloride 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil hydrochloride 10 mg tablets.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6e9aacf9-abb6-4dec-9a8d-4eabf934d512 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for donepezil hydrochloride 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil hydrochloride 10 mg tablets.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1a8906ce-96dc-4bc8-81c1-5db67a187aac (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer's disease, following oral dosing, peak plasma concentration is achieved for donepezil hydrochloride 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil hydrochloride 10 mg tablets.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8090bff0-e0f0-4846-a2ab-cb28a0a2648d (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for donepezil hydrochloride 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil hydrochloride 10 mg tablets.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7620f41a-3eef-453b-a564-ea3c85374de2 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for donepezil hydrochloride 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil hydrochloride 10 mg tablets.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e2ab403a-ec2d-44e7-9da1-66d0a7443f1d (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for donepezil hydrochloride 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil hydrochloride 10 mg tablets.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:06dd25a5-1bf2-446d-ad75-ff9d55117660 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for donepezil hydrochloride 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil hydrochloride 10 mg tablets.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:98e451e1-e4d7-4439-a675-c5457ba20975 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for ARICEPT 23 mg tablets in approximately 8 hours, compared with 3 hours for ARICEPT 10 mg tablets.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:297e86e8-d248-4cc9-9d9c-2ef9efb4414d (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for donepezil 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil 10 mg tablets.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7ab9d0ef-e30c-46e9-9911-435a7b65c47b (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for donepezil 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil 10 mg tablets.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:de96349a-5fee-4de9-921c-e453d44b3203 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for donepezil hydrochloride 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil hydrochloride 10 mg tablets.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:56abe961-ec94-4a77-b548-426f6255539e (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for donepezil hydrochloride 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil hydrochloride 10 mg tablets.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3257494f-8f44-4978-b92d-bde87b2444b6 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for donepezil hydrochloride 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil hydrochloride 10 mg tablets.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ac857917-74db-4591-be9f-d1c822c68c81 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for donepezil hydrochloride 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil hydrochloride 10 mg tablets.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:385d2fb5-814c-44bd-ac7b-8857d18f144b (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for donepezil 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil 10 mg tablets.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4747633b-ac32-455e-8d50-ce9c481480c0 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for donepezil hydrochloride 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil hydrochloride 10 mg tablets.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:79ad107b-bb20-4ed3-89f0-d7c862f3957c (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for donepezil hydrochloride 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil hydrochloride 10 mg tablets.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:86b0c5a0-ff3c-4840-a4ac-82af922d58bf (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for donepezil hydrochloride 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil hydrochloride 10 mg tablets.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:03e26183-3e07-45e8-a414-a8bad32483e2 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer's disease, following oral dosing, peak plasma concentration is achieved for donepezil hydrochloride 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil hydrochloride 10 mg tablets.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:37fc6638-4a63-4582-a64c-3525f8ed7ef2 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for donepezil hydrochloride 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil hydrochloride 10 mg tablets.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:11404dc3-1bde-4d4e-8386-006b67ee19dd (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer's disease, following oral dosing, peak plasma concentration is achieved for donepezil hydrochloride 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil hydrochloride 10 mg tablets.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7c0d3bcb-157d-0414-64ee-055bc614d190 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for donepezil hydrochloride 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil hydrochloride 10 mg tablets.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aa2c22b8-2dd4-4916-bc4f-9995eab74a6e (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for donepezil hydrochloride 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil hydrochloride 10 mg tablets.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:caebc31c-5a35-4434-b7e2-80f6405383ca (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        Based on population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer’s disease, following oral dosing, peak plasma concentration is achieved for donepezil hydrochloride 23 mg tablets in approximately 8 hours, compared with 3 hours for donepezil hydrochloride 10 mg tablets.

  6. Projected row 466

    Medicine slug
    donepezil
    Compared field
    volumeOfDistribution
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    52
    Source count
    52
    Agreement rate
    0.961538
    Recorded readings

    1. 12 - 16 L/kg

      Numeric value
      12
      Unit
      L/kg
      Source records
      50

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 50 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5d46ef3c-0dee-4389-a2d5-997ea8342817 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12 - 16 L/kg.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1c6e8d7f-5219-4b6c-a1ce-2baff28c3d55 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12 to 16 L/kg.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:12ae85f0-023c-49ca-8c4a-0a6a7585290e (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12 to 16 L/kg.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:48178cb4-4fee-47c0-88e9-a4f017f1f448 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12-16 L/kg.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9407258b-60ed-4884-a903-885aeedaddf8 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12 to 16 L/kg.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c030fd7c-da5c-457a-a825-1767bd87d04d (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12 to 16 L/kg.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0516d548-db9b-410a-aec9-79aedbc3f6e9 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12 to 16 L/kg.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c942a4c9-dbe5-4131-bb6c-aa2d31b387e7 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12 to 16 L/kg.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ecf91436-9de1-44bb-8366-8551479c86a9 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12 - 16 L/kg.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c7e1f642-1bdc-4ed6-9b9e-c1af40b926cd (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12 to 16 L/kg.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:76bf638e-dbde-418e-8977-1caf009990bc (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12 to 16 L/kg.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8138f616-83f3-4c47-84ef-1bce2db339f7 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12 to 16 L/kg.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:32709bda-53d0-4d57-9f0b-3e1f28e39f25 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12-16 L/kg.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:37aa1285-774a-4714-a4af-4e3fa9fa7f55 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12 - 16 L/kg.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7db089de-0344-4246-81b7-7c88a2a18402 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12 - 16 L/kg.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:11ac01f4-d26e-47b2-9660-d514ab097fdb (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12 to 16 L/kg.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ee54a472-6783-41df-b8bb-9c3e4c996907 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12 - 16 L/kg.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a085ed33-c262-44ab-e053-2a95a90a5557 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12-16 L/kg.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:12a755c5-1ad9-43d1-832a-eb2ff17bd693 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12-16 L/kg.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2d01fb96-c825-fad5-e063-6394a90ac6cc (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12 to 16 L/kg.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0c6b12e8-1933-40d8-bf43-97339b2b54fb (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12-16 L/kg.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:93dddf28-094b-dd8c-e053-2995a90a63e9 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12 - 16 L/kg.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:84d8ca68-26f3-4dd5-9dd4-6a7525a30db1 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12 to 16 L/kg.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c777ddc9-0b61-4d6f-95d6-818ba1861d62 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12 to 16 L/kg.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1a8906ce-96dc-4bc8-81c1-5db67a187aac (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12-16 L/kg.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8090bff0-e0f0-4846-a2ab-cb28a0a2648d (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12-16 L/kg.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bc570682-413b-46fb-a069-c2986884bfce (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12 to 16 L/kg.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7620f41a-3eef-453b-a564-ea3c85374de2 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12-16 L/kg.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cb1b3ed1-6e68-08e2-e053-2995a90a68c4 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12 - 16 L/kg.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e2ab403a-ec2d-44e7-9da1-66d0a7443f1d (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12 to 16 L/kg.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:06dd25a5-1bf2-446d-ad75-ff9d55117660 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12-16 L/kg.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:98e451e1-e4d7-4439-a675-c5457ba20975 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12-16 L/kg.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c26d9bf3-e148-48bb-8f4f-e8c73804b311 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12 - 16 L/kg.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:297e86e8-d248-4cc9-9d9c-2ef9efb4414d (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12 - 16 L/kg.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7ab9d0ef-e30c-46e9-9911-435a7b65c47b (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12 - 16 L/kg.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:de96349a-5fee-4de9-921c-e453d44b3203 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12 to 16 L/kg.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3257494f-8f44-4978-b92d-bde87b2444b6 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12 to 16 L/kg.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ac857917-74db-4591-be9f-d1c822c68c81 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12-16 L/kg.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:385d2fb5-814c-44bd-ac7b-8857d18f144b (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12 - 16 L/kg.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:41c095b6-acd9-4627-a813-bbca7ecafee5 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12-16 L/kg.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:042a59ea-131a-4806-b0f4-2f791d4414e2 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12-16 L/kg.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4747633b-ac32-455e-8d50-ce9c481480c0 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12-16 L/kg.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:79ad107b-bb20-4ed3-89f0-d7c862f3957c (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12 to16 L/kg.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:86b0c5a0-ff3c-4840-a4ac-82af922d58bf (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12 to 16 L/kg.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:03e26183-3e07-45e8-a414-a8bad32483e2 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12 to 16 L/kg.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:37fc6638-4a63-4582-a64c-3525f8ed7ef2 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12 to 16 L/kg.
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:11404dc3-1bde-4d4e-8386-006b67ee19dd (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12 - 16 L/kg.
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7c0d3bcb-157d-0414-64ee-055bc614d190 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12 to 16 L/kg.
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aa2c22b8-2dd4-4916-bc4f-9995eab74a6e (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12-16 L/kg.
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:caebc31c-5a35-4434-b7e2-80f6405383ca (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12-16 L/kg.

    2. 12 L/kg

      Numeric value
      12
      Unit
      L/kg
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6e9aacf9-abb6-4dec-9a8d-4eabf934d512 (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12 L/kg to 16 L/kg.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:56abe961-ec94-4a77-b548-426f6255539e (opens source in a new tab)

        Donepezil label

        Version not recorded · Effective date not recorded

        The steady state volume of distribution is 12 L/kg to 16 L/kg.

  7. Projected row 467

    Medicine slug
    dopamine
    Compared field
    volumeOfDistribution
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    19
    Source count
    7
    Agreement rate
    1
    Recorded readings

    1. 0.6 to 4 L/kg

      Numeric value
      0.6
      Unit
      L/kg
      Source records
      7

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 7 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0e499952-46c7-4172-8c70-186312e240a3 (opens source in a new tab)

        Dopamine label

        Version not recorded · Effective date not recorded

        The reported apparent volume of distribution in neonates was 0.6 to 4 L/kg, leading to an elimination half life of 5 to 11 minutes.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:38431050-007e-41b2-e063-6394a90a1d64 (opens source in a new tab)

        Dopamine label

        Version not recorded · Effective date not recorded

        The reported apparent volume of distribution in neonates was 0.6 to 4 L/kg, leading to an elimination half life of 5 to 11 minutes.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:460906f7-b532-4ddb-a799-ad7b50488143 (opens source in a new tab)

        Dopamine label

        Version not recorded · Effective date not recorded

        The reported apparent volume of distribution in neonates was 0.6 to 4 L/kg, leading to an elimination half life of 5 to 11 minutes.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fc1eb709-ce72-413e-9043-8e463ef0fd36 (opens source in a new tab)

        Dopamine label

        Version not recorded · Effective date not recorded

        The reported apparent volume of distribution in neonates was 0.6 to 4 L/kg, leading to an elimination half life of 5 to 11 minutes.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:45b0729e-529b-02f6-e063-6294a90a31d3 (opens source in a new tab)

        Dopamine label

        Version not recorded · Effective date not recorded

        The reported apparent volume of distribution in neonates was 0.6 to 4 L/kg, leading to an elimination half life of 5 to 11 minutes. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Dopamine is a natural catecholamine formed by the decarboxylation of 3,4 dihydroxyphenylalanine (DOPA).
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1f306ad2-3606-4525-5a8a-ce78f426c1a2 (opens source in a new tab)

        Dopamine label

        Version not recorded · Effective date not recorded

        The reported apparent volume of distribution in neonates was 0.6 to 4 L/kg, leading to an elimination half life of 5 to 11 minutes. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Dopamine is a natural catecholamine formed by the decarboxylation of 3,4 dihydroxyphenylalanine (DOPA).
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7896052c-2a72-ca89-e053-2a91aa0ae86e (opens source in a new tab)

        Dopamine label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution in neonates is reported as 0.6 to 4 L/kg, leading to an elimination half-life of 5 to 11 minutes.

  8. Projected row 468

    Medicine slug
    doravirine
    Compared field
    bioavailability
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    2
    Source count
    2
    Agreement rate
    1
    Recorded readings

    1. 64%

      Numeric value
      64
      Unit
      %
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:76ce1f00-28c0-4314-bd2c-d473fe3d0970 (opens source in a new tab)

        Doravirine label

        Version not recorded · Effective date not recorded

        ic coefficient of variation) AUC 0-24 (mcg∙h/mL) 16.1 (29) C max (mcg/mL) 0.962 (19) C 24 (mcg/mL) 0.396 (63) Time to Steady State (Days) 2 Accumulation Ratio 1.2 to 1.4 Absorption Absolute Bioavailability 64% T max (h) 2 Effect of Food Geometric mean ratio [high-fat meal/fasting] and (90% confidence interval) for PK parameters.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ff06e5cc-f47a-4779-816b-0e5b13e88a25 (opens source in a new tab)

        Doravirine label

        Version not recorded · Effective date not recorded

        ic coefficient of variation) AUC 0-24 (mcg∙h/mL) 16.1 (29) C max (mcg/mL) 0.962 (19) C 24 (mcg/mL) 0.396 (63) Time to Steady State (Days) 2 Accumulation Ratio 1.2 to 1.4 Absorption Absolute Bioavailability 64% T max (h) 2 Effect of Food Geometric mean ratio [high-fat meal/fasting] and (90% confidence interval) for PK parameters.

  9. Projected row 469

    Medicine slug
    doravirine
    Compared field
    proteinBinding
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    2
    Source count
    2
    Agreement rate
    1
    Recorded readings

    1. 76%

      Numeric value
      76
      Unit
      %
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:76ce1f00-28c0-4314-bd2c-d473fe3d0970 (opens source in a new tab)

        Doravirine label

        Version not recorded · Effective date not recorded

        AUC Ratio 1.16 (1.06, 1.26) C max Ratio 1.03 (0.89, 1.19) C 24 Ratio 1.36 (1.19, 1.55) Distribution V dss (L) Based on IV dose 60.5 Plasma Protein Binding 76% Elimination t 1/2 (h) 15 CL/F (mL/min) 106 (35.2) CL renal (mL/min) 9.3 (18.6) Metabolism Primary Pathway(s) CYP3A Excretion Major Route of Elimination Metabolism Urine (unchanged) 6% Biliary/Fecal (unchanged) Minor Specific Populations In a
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ff06e5cc-f47a-4779-816b-0e5b13e88a25 (opens source in a new tab)

        Doravirine label

        Version not recorded · Effective date not recorded

        AUC Ratio 1.16 (1.06, 1.26) C max Ratio 1.03 (0.89, 1.19) C 24 Ratio 1.36 (1.19, 1.55) Distribution V dss (L) Based on IV dose 60.5 Plasma Protein Binding 76% Elimination t 1/2 (h) 15 CL/F (mL/min) 106 (35.2) CL renal (mL/min) 9.3 (18.6) Metabolism Primary Pathway(s) CYP3A Excretion Major Route of Elimination Metabolism Urine (unchanged) 6% Biliary/Fecal (unchanged) Minor Specific Populations In a

  10. Projected row 470

    Medicine slug
    doxazosin
    Compared field
    bioavailability
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    67
    Source count
    67
    Agreement rate
    0.985075
    Recorded readings

    1. 65%

      Numeric value
      65
      Unit
      %
      Source records
      66

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 66 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9f67fa58-f623-4145-9e2c-98feee7ca45f (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:40e47e75-6a47-323b-e054-00144ff8d46c (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2830533c-ccdf-4401-b19c-763eeb1bc0a7 (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b4c974ad-cbd6-4811-ab48-461e7ffa99f7 (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3f4dc1a7-05e6-41d7-908c-30ce2677d87b (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d42d2691-f25d-4dfc-99d0-3286d71480a4 (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:de9ab9a4-d8b8-8b36-e053-2a95a90aaa35 (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:57f4a953-ad23-4a44-9956-c48aa5927132 (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:64a19cb1-79fc-8b0b-e053-2a91aa0aaa94 (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:30b709d6-c438-c721-e063-6294a90abd61 (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f306adae-a2fe-5477-e053-2995a90a7838 (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3354196f-bbcf-4bc5-94f6-e6e8e132acb1 (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2e524986-7903-416f-b2b8-d27295103e75 (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:08521333-ff21-45ad-b99e-1f43d945d24d (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7991373e-8a62-47f9-b4fb-90573485af4e (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0d9df8e9-f823-4ff8-a5fe-0309dd132b04 (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b364c7a8-72b5-4776-a500-400c37a72c9b (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:187bc51b-7a3a-5910-e063-6294a90aa888 (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54549d19-6311-4dbb-8622-fd3e5440551a (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6b887aa5-5edf-48c5-a480-dea8c35afa9d (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:44bfe5d7-a56a-46f1-8ef3-ad386ab35f0f (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8de7d5ee-7f9d-447a-af76-7a7fbf3eb33d (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7e547752-a53a-4ad9-b70e-7cc2a1dd5d5d (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:46b01b1d-c48a-4c36-bf3c-bba98066166c (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b57cf33b-e0bd-54e9-e053-2a95a90a5a6a (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e3d381c1-3b2f-af70-f4e6-08d6202eed25 (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:71815e8f-33ed-4f36-a8ec-d4443151a9d8 (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bfea0b5b-9354-490f-88ff-008134077d24 (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:30a6bb83-f91b-4c4f-a849-4f2be3735a0e (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0aaa68a7-f73b-46d8-860f-a76d96897489 (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6fbb9ca2-e8ca-45c7-a178-b4c8dd7a9a1f (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e4758bf9-b9d4-4268-beb8-0d7e06890895 (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f1dc70f6-4329-46da-8990-7bd6eec9d37d (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ac4cd22b-2a03-47b6-9eed-550be278f17d (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b5d1c604-ce3b-4973-845f-9db267a945cd (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8641cdb1-dc16-4a13-8a84-bc8f6d58b4d4 (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5e1f5e49-2da1-43ab-9795-228a8bcc5a82 (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e2f5d7d2-21aa-4921-8035-da945d3c565c (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:508b908e-8d80-422e-8ec0-2081185f4c95 (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7aeaa0e1-136c-444d-b66c-7a5a96fb3022 (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:277c3278-4fe2-47ac-9115-15b417325ffd (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ec06f008-37a1-4757-a3ee-0b4720912bc4 (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54eeef3d-c906-37e7-e063-6294a90afca2 (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2ea9bb6b-a4f0-496a-b27b-4454167a4b70 (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a7f589b0-eebb-48cb-912f-a4bd956e4dcb (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4fa5c2f7-cda9-56cd-622f-b3d05dc7c94b (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f6c9856e-9154-f349-e053-6294a90a9f2c (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:93f2d724-5a54-4721-b04a-e46bc764607b (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1d8ff659-8129-4dca-9e8f-13b97240d1e1 (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:64a243e6-7056-115d-e053-2a91aa0a510f (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ef8b5534-5939-400a-ad5e-f9ceaefc4097 (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3ab222b7-74cc-5343-e063-6294a90a9616 (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:445dc831-1960-4b25-e063-6294a90a6efd (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54116886-ea5e-5320-e054-00144ff8d46c (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4034fb6d-f55d-4df0-b500-d6a413591f6e (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8c0c0345-833b-4a3d-9081-da66b208d750 (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      57. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6b74b18f-b89a-4109-a29e-c4fa65a3c5ee (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      58. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:88efdfb0-710f-768a-e053-2995a90aede4 (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      59. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2e5cd8cb-7d43-e7af-e063-6294a90a310e (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      60. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2110eec5-949d-4718-ad6d-3629e5db8a07 (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      61. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:505d3c4c-5506-72cc-e054-00144ff88e88 (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      62. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9b6170e7-814a-46ef-b068-cf3e6508d5e1 (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      63. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f2b35586-d550-3fcb-e053-2995a90a3403 (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      64. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e046e0b7-f510-4318-9884-034d683864d4 (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      65. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bf2f7b41-f14d-4fcd-8db3-f507ca6ff78b (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.
      66. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:eefc47bc-c10f-49bb-8ef7-5999f798ab39 (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        Bioavailability is approximately 65%, reflecting first-pass metabolism of doxazosin by the liver.

    2. 54%

      Numeric value
      54
      Unit
      %
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:355bcdce-0481-48ba-8ebd-2009106aaf77 (opens source in a new tab)

        Doxazosin label

        Version not recorded · Effective date not recorded

        The relative bioavailability of CARDURA XL compared with doxazosin IR was 54% at the 4 mg dose and 59% for the 8 mg dose.

Access

Query or download the projection

View this filtered page as JSONDownload up to 200 filtered CSV rows
GET /api/datasets/source-consensus?limit=10&offset=460

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
state
Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
field
Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy